Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis
Authors' conclusion
Autoantibodies associated with anti-TIF1γ were found in isolation and in combination among a subset of patients with JDM. Patients with these autoantibodies had less severe muscle disease and were not enriched for HLA-DRB1*03.
Study context
- Population
- Patients with anti-TIF1γ autoantibody-positive JDM and juvenile healthy controlsplus 90 healthy controls
- Participants
- 150 patients
- Exposure
- Anti-TIF1γ JDM with vs without anti-TIF1γ-associated autoantibodies
- Any associated autoantibodyn = 44
- Healthy controlsn = 90
- Outcome
- Prevalence of anti-CCAR1, anti-C1Z1, anti-IMMT, anti-TBL1XR1 and anti-Sp4 autoantibodies and their associated features
Main finding
As reported in the abstract
Prevalence of anti-TIF1γ-associated autoantibodies in anti-TIF1γ JDM
- Any anti-TIF1γ-associated autoantibody
- 44 (29%)
- Anti-Sp4
- 25 (17%)
- Anti-TBL1XR1
- 22 (15%)
- Anti-CCAR1
- 14 (9%)
- Anti-C1Z1
- 2 (1%)
- Anti-IMMT
- 2 (1%)
Observational data: associations, not effects.
Further findings
| Outcome | Any associated autoantibody | Without associated autoantibodies | P value |
|---|---|---|---|
| FallingAny associated autoantibody vs Without associated autoantibodies | 34% | 53% | P = 0.032 |
Falling
- Lower peak muscle enzymes with any associated autoantibody
Cancer
- None of the patients had cancer
- 0
HLA-DRB1*03 and any anti-TIF1γ-associated autoantibody (White patients)
- OR (protective)
- 0.20 (95% CI 0.07-0.52)
Original publication
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis. Arthritis Rheumatol. Published 30 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →